Sanofi - Corporate Presentation

1. 2015 I CORPORATE PRESENTATION
HOPE, it’s what Sanofi brings each day,
responding to the new challenges
of protecting the health of seven billion
people
VIDEO HOPE
© Denis FelixJune 11, 2015

2. SANOFI AT A GLANCE
OUR HERITAGE
OUR STRATEGY
OUR COMMITMENTS
OUR 3 BUSINESS SEGMENTS
OUR INNOVATION IN R&D
OUR RESPONSIBILITY
OUR KEY FIGURES
OUR PRESENCE
CORPORATE PRESENTATION – JUNE 11, 2015 2

3. SANOFI
AT A GLANCE
3
© Denis Felix
CORPORATE PRESENTATION – JUNE 11, 2015

4. SANOFI AT A GLANCE
OUR
HERITAGE
A long tradition
in health
4
Hoechst
Marion
Roussel
1997
Roussel
1911
Marion
1950
Hoechst
1863
Synthélabo
1970
Delalande
1924
Delagrange
1931
Robert
& Carrière
1901
Dausse
1834
BMP Sunstone, Medley,
Merial, Nepentes, Zentiva,
Kendricks, Oenobiol, Chattem,
Acambis, Symbion, Shantha
Biotechnics , Fovea, Bipar
Sciences, Targegen, Genfar,
Globalpharma
2008-2015
Genzyme
2011
Sanofi-aventis
2004
Aventis
1999
Sanofi-Synthélabo
1999
Sanofi Pasteur
2004
Sterling
1901
Midy
1718
Clin Midy
1971
Chinoin
1919
Sanofi
1973
Connaught
1922
Rorer
1910
Rhône-Poulenc
Rorer
1990
Institut
Mérieux
1897
Wittman
& Poulenc
1860
CORPORATE PRESENTATION – JUNE 11, 2015

5. SANOFI AT A GLANCE
OUR
STRATEGY
5
SEIZEVALUE-ENHANCING
GROWTH OPPORTUNITIES
ADAPTSTRUCTURE FOR
FUTURE CHALLENGES
& OPPORTUNITIES
BRINGINNOVATIVE PRODUCTS
TO MARKET
Delivering
sustainable
long-term
growth by:
GROWA GLOBAL HEALTHCARE
LEADER WITH SYNERGISTIC
PLATFORMS
© Guillaume Ramon/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015

6. SANOFI AT A GLANCE
6
Our mission
We act with our partner to protect health, enhance life
and respond to the hopes and potential healthcare
needs of 7 billion people around the world.
3 business segments
Pharma Human
vaccines
Animal
Health
3 Commitments
Exploring
the boundaries
of medical
innovation
for patients
Preventing
disease
and
supporting
patients
Improving
access
to healthcare
More than
110,000
employees
Present in
100
countries
€33.8 bn
In sales 2014
CORPORATE PRESENTATION – JUNE 11, 2015

7. SANOFI AT A GLANCE
OUR MISSION
We act with our partners
to protect health, enhance life,
provide hope and respond
to the potential healthcare needs
of 7 billion people around the world.
With our global footprint
and commitment to improving
access to medicines
and healthcare, we work tirelessly
to make a difference to people’s
lives every day and transform
scientific innovations into therapeutic
solutions for patients.
7
© G. Blonsky/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015

8. SANOFI AT A GLANCE
OUR
COMMITMENTS
8
1
EXPLORING
THE BOUNDARIES
OF MEDICAL INNOVATION
Sanofi is committed to a more open
and productive Research & Development
model, focused on patient needs
and based on biotechnology.
This model significantly accelerates
the pace and enhances the productivity
of research, driving the development
of more effective health solutions in major
therapeutic areas.
Between 2014 and 2020, more than
18 potential launches are anticipated.
© Pierre-Olivier/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015

9. SANOFI AT A GLANCE
OUR
COMMITMENTS
9
2
PREVENTING DISEASES
AND SUPPORTING PATIENTS
Improved quality of life and longer life
expectancy, coupled with increased
prevalence of chronic disease are
contributing to the evolution of today’s
main healthcare challenges.
Sanofi promotes
prevention through vaccination
and support for patients.
The Group’s commitment goes beyond
a medication: it is based
on understanding and listening to patients
to provide integrated health solutions
and personalized treatment.
© Pierre-Olivier/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015

10. SANOFI AT A GLANCE
© Denis Felix
OUR
COMMITMENTS
10
3
IMPROVING ACCESS
TO HEALTHCARE
Healthcare needs vary from continent
to continent. While the northern
hemisphere is marked by an aging
population, the southern is characterised
by demographic growth, urbanization,
and a rise in chronic diseases.
To meet the many different healthcare
needs of the seven billion inhabitants
of our planet and improve their access
to treatment, Sanofi has established
a global presence in more than
100 countries, a specific product
portfolio for each market and
a leadership position in Emerging
markets.
CORPORATE PRESENTATION – JUNE 11, 2015

11. SANOFI AT A GLANCE
OUR
3 BUSINESS
SEGMENTS
11
HUMAN
VACCINES
>Pediatric vaccines
>Influenza vaccines
>Booster vaccines
for adults
and adolescents
>Meningitis
vaccines
>Vaccines
for travelers
and endemic
areas
ANIMAL
HEALTH
PHARMA
PRODUCTS
>Anti-parasitics
>Anti-infectives
>Anti-inflammatories
>Anti-ulceratives
VACCINES
>Foot and mooth
disease
>Rabies and pets
vaccines Range
>Avian vaccines
PHARMA
>Diabetes
>Cardiovascular
disease
>Rare diseases
>Multiple sclerosis
>Oncology
>Consumer
Health care
>Generics
Net sales
€27,720 M
Net sales
€3,974 M
Net sales
€2,076 M
© G. Blonsky/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015

12. SANOFI AT A GLANCE
OUR
INNOVATION
IN R&D
12
€4.8bn
Invested in R&D
in 2014
5
R&D HUBS
Across Europe,
North America
and Asia-Pacific
43
molecules
and vaccines
in the R&D
portfolio including
14 in late stage*
Up to
18 launches
expected
between
2014 and 2020
*Annual results, Feb. 2015
Diabetes Toujeo
Afrezza
Lixilan
Lyxumia
Insulin pro
Uncontrolled
Hypercholesterolemia
Praluent®
Pediatric
Vaccines
Shan 5
PR5i-6-1
Rotavirus vaccine
Rare disease
Familial amyloid
polyneuropathy
Patisiran
Dengue Dengue vaccine
Clostridum Difficile C.Diff vaccine
Multiple Sclerosis Lemtrada
Oncology SAR650984
Type 1
Gaucher disease
Cerdelga
Severe asthma dupilumab
Dogs Fleas and ticks Nexgard®
Rheumatoid arthritis sarilumab
CORPORATE PRESENTATION – JUNE 11, 2015

13. SANOFI AT A GLANCE
CORPORATE
SOCIAL
RESPONSIBILITY
13
© Pierre–Olivier/Capa Pictures
Each day, across the globe,
Sanofi’s 110,000 employees are working
to protect the health and improve access
to healthcare for as many patients
as possible.
As a healthcare company, Sanofi places
quality, safety, ethics, and respect
for the planet at the heart of its business.
More than
300 access
to healthcare
programs
in more
than 80 countries
1/3
of the global
population
has no access
to healthcare
More than
190 million
people benefited
PARTNERING TO PROMOTE
ACCESS TO HEALTHCARE
CORPORATE PRESENTATION – JUNE 11, 2015

14. SANOFI AT A GLANCE
14
Improve access to medicines in the most
deprived countries with an access to medicines
department whose holistic approach acts
on several levels:
> Tiered-pricing for affordable medicines
> Information, training and education programs
> Innovative research
> Partnerships on the ground to ensure program
success
Reduce health inequalities
through its ’programs
dedicated to:
> Childhood cancer
> Maternal and neonatal mortality
> Access to healthcare for the world’s most
needy communities.
Promoting quality care by fighting against
counterfeit medicines.
CORPORATE
SOCIAL
RESPONSIBILITY
© Rémi DUHAMEL - Image in Production
CORPORATE PRESENTATION – JUNE 11, 2015

15. SANOFI AT A GLANCE
OUR
KEY FIGURES
2014
15
BY ACTIVITIES
(in million euros)
BY GEOGRAPHICAL AREA
(in million euros)
EMPLOYEES BY ACTIVITIES
EMPLOYEES BY GEOGRAPHICAL AREA
€33.8 bn
Net sales
Animal Health
2,076
Pharma
27,720
Vaccines
3,974
More than
110,000
employees
worldwide
United States
11,339
Other countries
3,219
Emerging
markets
11,347
Western
Europe
7,865
Animal Health
6,109
Pharma
93,393
Vaccines
13,994
Other countries
41,528
North America
18,627Europe
53,341
Emerging Markets: The world excluding the United States, Canada, Western Europe, Japan, Australia and New Zealand.
CORPORATE PRESENTATION – JUNE 11, 2015

16. SANOFI AT A GLANCE
OUR
PRESENCE
16
In more than
100 countries
107
Industrial sites
in 40 countries
More than
20
R&D sites
worldwide
CLOSER TO OUR PATIENTS AND PARTNERS
EUROPE
48 Manufacturing sites
6 Development centers
33 Distribution Hubs
NORTH AMERICA
19 Manufacturing sites
2 Development centers
8 Distribution Hubs
ASIA-PACIFIC
20 Manufacturing sites
5 Development centers
30 Distribution Hubs
LATIN AMERICA
12 Manufacturing sites
3 Development centers
30 Distribution Hubs
AFRICA-MIDDLE-EAST
8 Manufacturing sites
1 Development center
58 Distribution Hubs
CORPORATE PRESENTATION – JUNE 11, 2015

17. RECOMMENDATIONS
Forward Looking Statements
This document contains forward-looking statements as defined in the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are generally identified
by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar
expressions. Although Sanofi’s management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or projected by, the forward-
looking information and statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and analysis, including
post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that may be filed for any
such product candidates as well as their decisions regarding labeling and other matters that could
affect the availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from
external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of
cost containment policies and subsequent changes thereto, the average number of shares
outstanding as well as those discussed or identified in the public filings with the SEC and the AMF
made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended
December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
17
This corporate presentation
is available for all employees
of the Sanofi Group.
It may be used internally
or externally for presentations
of the Group, either in whole
or in part, as needed.
The information is taken
from Sanofi’s annual report on
Form 20-F 2014, annual results
2014 and press releases.
Further information
is available on www.sanofi.com
CORPORATE PRESENTATION – JUNE 11, 2015

18. Further information:
www.sanofi.com
SANOFI
COMMUNICATION CORPORATE
54, rue La Boétie
75008 Paris, France
Tel. +33 (0)1 53 77 40 00
CORPORATE PRESENTATION 2015 18